Kimia Biosciences has fixed September 21, 2026 as the record date for determining voting eligibility for its 33rd Annual General Meeting. The AGM is scheduled for September 28, 2026.

The company submitted the notice and annual report to the BSE on September 4, 2026, pursuant to Regulation 34(1) of the SEBI LODR Regulations, 2015.

Meeting and Voting Schedule

The AGM will begin at 3:00 pm IST. Shareholders whose names appear in the Register of Members or Beneficial Owners maintained by depositories as on the cut-off date of September 21, 2026, are entitled to vote.

Remote e-voting will be available through National Securities Depository Limited (NSDL). The window opens on September 25, 2026, at 9:00 am and closes on September 27, 2026, at 5:00 pm.

Document Availability

The notice and annual report are accessible on the company website, the BSE website, and the NSDL e-Voting platform. Abhishek Kumar Pandey, Company Secretary & Compliance Officer, signed the submission from New Delhi.

Kimia Biosciences Limited reported a significant contraction in profitability for the first quarter of FY27, with net profit falling 41% year-on-year to ₹35.58 lakh. The decline followed a 12.1% drop in revenue from operations to ₹2,072.25 lakh, compared to ₹2,358.41 lakh in Q1FY26.

The board of directors approved the unaudited standalone financial results at a meeting held on August 10, 2026. The results were subsequently published in "Financial Express" and "Jansatta" on August 12, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Revenue pressure was evident as total income fell to ₹2,080.31 lakh from ₹2,443.10 lakh in the prior-year quarter. While other income dropped sharply to ₹8.06 lakh from ₹84.69 lakh, the primary drag on margins came from the cost structure. Cost of materials consumed increased by 2.9% to ₹1,656.88 lakh, even as the company benefited from a ₹533.54 lakh reduction in finished goods and work-in-progress inventories.

Operating expenses remained relatively stable, with employee benefits declining slightly to ₹296.97 lakh and finance costs dropping significantly to ₹83.05 lakh from ₹174.71 lakh. However, these savings were insufficient to offset the revenue decline and higher material costs. Deferred tax charges stood at ₹13.40 lakh for the quarter.

What the Numbers Show

A notable divergence exists between the company’s top-line performance and its input costs. While revenue contracted by over 12%, the cost of materials consumed actually rose by nearly 3%. This inverse movement suggests potential pricing pressures or a shift in product mix toward lower-margin items, eroding the gross operating leverage typically seen in pharmaceutical manufacturing during periods of volume growth. Additionally, the sharp drop in finance costs indicates a reduction in interest-bearing debt or favorable refinancing, yet this benefit did not translate into proportional bottom-line protection due to the revenue shortfall.